Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Januar 2021 09:00 ET | Quelle: CohBar, Inc.

CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
09. Dezember 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
19. November 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference

MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
16. November 2020 16:01 ET | Quelle: CohBar, Inc.

CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
02. November 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020

MENLO PARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
29. Oktober 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis

MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
27. Oktober 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
26. Oktober 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

MENLO PARK, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
15. Oktober 2020 16:05 ET | Quelle: CohBar, Inc.

CohBar to Present at the BIO-Europe Conference

MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
08. Oktober 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference

MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...

Vorherige Seite

Nächste Seite